

Vibe Bioscience Ltd.
(Formerly Altitude Resources Inc.)

Condensed Interim Consolidated Financial Statements

For the three and six months ended January 31, 2019

(Expressed in Canadian Dollars)

(unaudited)

Vibe Bioscience Ltd.
(Formerly Altitude Resources Inc.)
Condensed Interim Consolidated Financial Statements
For the three and six months ended January 31, 2019
(unaudited)

NOTICE TO SHAREHOLDERS

MANAGEMENT’S RESPONSIBILITY FOR CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

The accompanying unaudited condensed interim consolidated financial statements of Vibe Bioscience Ltd. (“Vibe”), formerly Altitude Resources Inc. (“Altitude”) are the responsibility of the Board of Directors. The unaudited condensed interim consolidated financial statements have been prepared by management, on behalf of the Board of Directors, in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board. These unaudited condensed interim consolidated financial statements do not include all of the disclosures required for annual financial statements and therefore should be read in conjunction with Altitude’s audited annual financial statements and notes thereto for the year ended July 31, 2017. These unaudited condensed interim consolidated financial statements follow the same significant accounting policies and methods of application as those included in Altitude’s most recent audited annual financial statements. Management acknowledges responsibility for the preparation and presentation of the financial statements, including responsibility for significant accounting judgments and estimates and the choice of accounting principles and methods that are appropriate to Altitude’s circumstances. In the opinion of management, the unaudited condensed interim consolidated financial statements have been prepared within acceptable limits of materiality and are in accordance with International Accounting Standard 34, Interim Financial reporting using accounting policies consistent with IFRS appropriate in the circumstances.

Management has established processes, which are in place to provide it sufficient knowledge to support management representations that it has exercised reasonable diligence that (i) the unaudited condensed interim consolidated financial statements do not contain any untrue statement of material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it is made, as of the date of, and for the periods presented by, the unaudited condensed interim consolidated financial statements and (ii) the unaudited condensed interim consolidated financial statements fairly present in all material respects the financial condition, results of operations and cash flows of Altitude, as of the date of, and for the period presented by, the unaudited condensed interim consolidated financial statements.

The Board of Directors is responsible for reviewing and approving the unaudited condensed interim consolidated financial statements and for ensuring that management fulfills its financial reporting responsibilities.

Management recognizes its responsibility for conducting Altitude’s affairs in compliance with established financial standards, and applicable laws and regulations, and for maintaining proper standards of conduct for its activities.

(Signed) “Mark Waldron”

President & Chief Executive Officer

(Signed) “Ryan Mercier”

Chief Financial Officer

AUDITOR INVOLVEMENT

The accompanying unaudited condensed interim consolidated financial statements of Vibe have been prepared by and are the responsibility of management. The unaudited condensed interim consolidated financial statements as at and for the three and six months ended January 31, 2019 have not been reviewed by Vibe’s auditors.

Vibe Bioscience Ltd.
(Formerly Altitude Resources Inc.)
Condensed Interim Consolidated Statements of Financial Position
(Expressed in Canadian Dollars)
As at January 31, 2019
(unaudited)

	Jan 31 2019	July 31 2018
Assets		
Current		
Cash and cash equivalents	\$ 6,012	\$ 187,431
Amounts receivable (Note 5)	57,137	338,961
Investments (Note 6)	423,837	227,425
Other prepaids	-	-
	486,986	753,817
Exploration and evaluation assets (Note 5)	-	-
Due from related party (Note 7)	12,779	12,779
	\$ 499,765	\$ 766,596
Liabilities		
Current		
Accounts payable and accrued liabilities	\$ 655,122	\$ 726,515
Due to related parties (Note 7)	27,138	27,138
Due on demand loan (Note 8)	41,093	39,883
	723,353	793,536
Shareholders' Equity		
Share capital (Note 9)	4,080,306	4,080,306
Warrants (Note 10)	600,735	600,735
Accumulated other comprehensive income/(losses)	72,918	(123,494)
Contributed surplus (Note 10)	420,025	420,025
Deficit	(5,397,572)	(5,004,512)
	(223,588)	(26,940)
	\$ 499,765	\$ 766,596

Approved by the Board _____
"Mark Waldron"
Director (Signed)

_____ *"Jim Meloche"*
Director (Signed)

Vibe Bioscience Ltd.
(Formerly Altitude Resources Inc.)
Condensed Interim Consolidated Statements of Changes in Equity
(Expressed in Canadian Dollars)
(unaudited)

	Share Capital Class "A" Voting Common Shares		Warrants	Contributed Surplus	Accumulated Other Comprehensive Loss	Deficit	Total Equity
	Number	Amount					
Balance, July 31, 2017	26,375,908	\$ 4,080,306	\$ 600,735	\$ 95,025	\$ -	\$ (2,987,460)	\$ 1,788,606
Net loss	-	-	-	-	-	(137,573)	(137,573)
Balance, January 31, 2018	26,375,908	\$ 4,080,306	\$ 600,735	\$ 95,025	\$ -	\$ (3,125,033)	\$ 1,651,033
Net loss	-	-	-	-	-	(1,879,479)	(1,879,479)
Settlement of accounts payable by shareholder (Note 11)	-	-	-	325,000	-	-	325,000
Unrealized loss on revaluation of investments (Note 6)	-	-	-	-	(123,494)	-	(123,494)
Balance, July 31, 2018	26,375,908	\$ 4,080,306	\$ 600,735	\$ 420,025	\$ (123,494)	\$ (5,004,512)	\$ (26,940)
Net loss	-	-	-	-	-	(393,060)	(393,060)
Unrealized gain on revaluation of investments (Note 6)	-	-	-	-	196,412	-	196,412
Balance, January 31, 2019	26,375,908	\$ 4,080,306	\$ 600,735	\$ 420,025	\$ 72,918	\$ (5,397,572)	\$ (223,588)

Vibe Bioscience Ltd.
(Formerly Altitude Resources Inc.)
Condensed Interim Consolidated Statements of Comprehensive Income/(Loss)
 (Expressed in Canadian Dollars)
For the three and six months ended January 31, 2019
(unaudited)

	Three months ended 31-Jan-19	Three months ended 31-Jan-18	Six months ended 31-Jan-19	Six months ended 31-Jan-18
Expenses				
Salaries	\$ 48,000	\$ 48,000	\$ 96,000	96,000
General expenses	138,905	14,012	297,060	41,573
Net loss	\$ (186,905)	\$ (62,012)	\$ (393,060)	(137,573)
Other comprehensive income items that may be reclassified to income				
Unrealized gain on revaluation of investments (Note 6)	196,412	-	196,412	-
Comprehensive income/(loss)	9,507	(62,012)	(196,648)	(137,573)
Loss per share				
Basic and diluted	\$ 0.00	\$ (0.00)	\$ (0.01)	\$ (0.01)
Weighted average number of common shares outstanding				
Basic and diluted	26,375,908	26,375,908	26,395,908	26,395,908

Vibe Bioscience Ltd.
(Formerly Altitude Resources Inc.)
Condensed Interim Consolidated Statements of Cash Flows
(Expressed in Canadian Dollars)
For the three and six months ended January 31, 2019
(unaudited)

	Three months ended 31-Jan-19	Three months ended 31-Jan-18	Six months ended 31-Jan-19	Six months ended 31-Jan-18
Cash provided by (used in)				
Operations				
Comprehensive income/(loss)	\$ 9,507	\$ (62,012)	\$ (196,648)	\$ (137,573)
Items not affecting cash				
Unrealized gain on revaluation of investments	(196,412)	-	(196,412)	-
Amortization	-	-	-	-
	(186,905)	(62,012)	(393,060)	(137,573)
Net changes in non-cash working capital				
Amounts receivable	(7,601)	70,136	281,824	593,377
Accounts payable and accrued liabilities	110,469	32,290	(70,183)	(111,050)
Prepaid expenses	-	-	-	(500)
	(84,037)	40,414	(181,419)	344,254
Investing				
Exploration and evaluation assets	-	-	-	(361,575)
Capital assets	-	-	-	-
	-	-	-	(361,575)
Net change in cash and cash equivalents	(84,037)	40,414	(181,419)	(17,321)
Cash and cash equivalents, beginning of period	90,049	570	187,431	58,305
Cash and cash equivalents, end of period	\$ 6,012	\$ 40,984	\$ 6,012	\$ 40,984

Vibe Bioscience Ltd.
(Formerly Altitude Resources Inc.)
Notes to the Condensed Interim Consolidated Financial Statements
(Expressed in Canadian Dollars)
For the three and six months ended January 31, 2019
(unaudited)

1. NATURE OF OPERATIONS

Vibe Bioscience Ltd. (“Vibe” or the “Company”) is the entity resulting from the three-cornered amalgamation of Vibe Bioscience Corporation, Altitude Resources Inc. (“Altitude”) and 2657152 Ontario Inc. that was completed on March 25, 2019. Vibe is an integrated cannabis company with cultivation and retail operations in California. Shares of Vibe are expected to commence trading on the Canadian Securities Exchange in early April 2019. The primary office of the Company is located at #214, 2505 – 17th Avenue SW, Calgary, Alberta, Canada, T3E 73V.

Until March 24, 2019, the Company was known as Altitude Resources Inc., a junior coal exploration company with an exploration focus in northwest Alberta.

On March 25, 2019, subsequent to the period end, the Company completed the transaction contemplated in the amalgamation agreement among Vibe Bioscience Corporation, Altitude and 2657152 Ontario Inc., a wholly owned subsidiary of Altitude (the “Transaction”). Completion of the Transaction was also conditional on Altitude disposing of all of its mining assets and liabilities as well as the shares of its wholly-owned subsidiary, Altitude Resources Ltd. (the “Altitude Dispositions”). The Altitude Dispositions constituted the sale of all, or substantially all, of the assets of the Company and required shareholder approval in accordance with the provisions of the *Business Corporations Act* (Ontario). The approval of the shareholders of Altitude was received through a vote at the meeting on January 24, 2019.

These financial statements reflect the financial position and results of operation as at and for the three and six-month periods ended January 31, 2019. As such, these financial statements contain the assets, liabilities, equity and operations related only to Altitude’s coal operations. There is no activity related to Vibe’s cannabis operations reflected in these financial statements.

The reader is also directed to review Note 15 – ***Subsequent events***.

These financial statements were authorized for issue by the board of directors on April 1, 2019.

2. GOING CONCERN

These consolidated financial statements have been prepared on the basis of accounting principles applicable to a going concern, which assume that Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations. While the Company has been successful in securing financings in the past, there can be no assurance that it will be able to do so in the future. Accordingly, these Financial Statements do not give effect to adjustments, if any that would be necessary should the Company be unable to continue as a going concern and, therefore, be required to realize its assets and liquidate its liabilities in other than the normal course of business and at amounts that may differ from those shown in the consolidated financial statements.

The reader is also directed to review Note 13(c) - ***Financial instruments – Liquidity risk***.

At January 31, 2019, the Company had working capital deficit of \$236,367 a net cash position of \$6,012 and an accumulated deficit of \$5,397,572. In order to meet its work commitments and planned exploration expenditures for its projects as well as further working capital requirements,

Vibe Bioscience Ltd.
(Formerly Altitude Resources Inc.)
Notes to the Condensed Interim Consolidated Financial Statements
(Expressed in Canadian Dollars)
For the three and six months ended January 31, 2019
(unaudited)

it will be required to complete a financing (debt or equity). See Note 15, Subsequent events, regarding the completion of the reverse takeover of Altitude by Vibe and the contemporaneous disposition of Altitude's operating subsidiary.

3. BASIS OF PRESENTATION

These unaudited condensed interim consolidated financial statements have been prepared in accordance with IAS 34 – Interim Financial Reporting on the basis of International Financial Reporting Standards ("IFRS"). IFRS represents standards and interpretations approved by the International Accounting Standards Board ("IASB"), and are comprised of IFRSs, International Accounting Standards ("IASs"), and interpretations issued by the IFRS Interpretations Committee ("IFRICs") or the former Standing Interpretations Committee ("SICs").

These unaudited condensed interim consolidated financial statements do not include all of the disclosures required for annual financial statements and therefore should be read in conjunction with the Altitude's audited annual financial statements and notes thereto for the year ended July 31, 2018. These unaudited condensed interim consolidated financial statements follow the same significant accounting policies and methods of application as those included in Altitude's most recent audited annual financial statements.

These unaudited condensed interim consolidated financial statements have been prepared on the historical cost basis except for certain financial instruments which have been measured at fair value. In the opinion of management, all adjustments considered necessary for a fair presentation have been included.

The presentation and functional currency of the Company is the Canadian dollar.

4. SIGNIFICANT ACCOUNTING POLICIES

The financial framework and accounting policies applied in the preparation of these unaudited condensed interim financial statements are consistent with those as disclosed in Altitude's most recently completed audited annual financial statements for the year ended July 31, 2018.

Recent Accounting Pronouncements

In July 2014, the IASB issued the final version of IFRS 9, Financial Instruments. The new standard replaces IAS 39, Financial instruments: recognition and measurement. The final amendments made in the new version include guidance for the classification and measurement of financial assets and a third measurement category for financial assets, fair value through other comprehensive income. The standard also contains a new expected loss impairment model for debt instruments measured at amortized cost or fair value through other comprehensive income, lease receivables, contract assets and certain written loan commitments and financial guarantee contracts. The standard is effective for annual periods beginning on or after January 1, 2018 and must be applied retrospectively with some exceptions. Restatement of prior periods in relation to the classification and measurement, including impairment, is not required.

The accounting pronouncement detailed below has been issued but becomes effective for annual periods beginning on or after January 1, 2019. The Company has not early adopted this standard and is currently evaluating the impact, if any, that this standard might have on its financial statements.

Vibe Bioscience Ltd.
(Formerly Altitude Resources Inc.)
Notes to the Condensed Interim Consolidated Financial Statements
(Expressed in Canadian Dollars)
For the three and six months ended January 31, 2019
(unaudited)

4. SIGNIFICANT ACCOUNTING POLICIES (cont.)

IFRS 16 - Leases sets out the principles for the recognition, measurement and disclosure of leases.

IFRS 16 provides revised guidance on identifying a lease and for separating lease and non-lease components of a contract. IFRS 16 introduces a single accounting model for all lessees and

requires a lessee to recognize right of-use assets and lease liabilities for leases with terms of more than 12-months, unless the underlying asset is of low value. Under IFRS 16, lessor accounting for operating and finance leases will remain substantially unchanged. IFRS 16 is effective for annual periods beginning on or after January 1, 2019, with earlier application permitted for entities that apply IFRS 15 Revenue from Contracts with Customers.

5. EXPLORATION AND EVALUATION ASSETS

	Jan 31, 2019	July 31, 2018
Balance beginning of period – Palisades Property	\$ -	\$ 2,472,984
Acquisition cost and leases	-	33,789
Exploration	-	717,144
JOGMEC contribution	-	(793,455)
Write down of Palisades Property	-	(2,430,462)
Balance end of year – Palisades Property	-	-
Balance beginning of year – Elan Coal Property	-	-
Exploration	-	-
Write down of Elan Coal Property	-	-
Reversal of write-down of Elan Coal Property	-	234,620
Disposition of Elan Coal Property	-	(234,620)
Balance ending of year – Elan Coal Property	-	-
	\$ -	\$ -

Palisades Property

The Company's 100% owned Palisades Property is comprised of six contiguous Alberta Crown Coal leases acquired directly from the Alberta Department of Energy between September 2010 and February 2011. Five of the leases are included within Alberta Department of Energy's Category 4 classification; the sixth lease is a combination of Category 4 and Category 2 lands. There are no work commitments associated with the Palisades Property. The only ongoing obligation is the payment of the annual lease (currently \$3.50 per hectare) for a 15 year period from the commencement of the leases.

Vibe Bioscience Ltd.
(Formerly Altitude Resources Inc.)
Notes to the Condensed Interim Consolidated Financial Statements
(Expressed in Canadian Dollars)
For the three and six months ended January 31, 2019
(unaudited)

5. EXPLORATION AND EVALUATION ASSETS (Cont'd)

The Palisades Property totals 4,648 hectares. It is located approximately 28 kilometres northwest of the town of Hinton, Alberta.

On April 8, 2015, the Company entered into the Joint Exploration Agreement with Japan Oil, Gas and Metals National Corporation (“JOGMEC”) to explore Palisades metallurgical coal project in West Central Alberta, Canada. Through a joint exploration arrangement JOGMEC has agreed to

acquire up to a 51% interest in the Company’s Palisades Coal Project based on the three (3) farm in milestones which include field work, drilling and completion of mining study.

During the First Farm-in period (ended on March 31, 2016), JOGMEC contributed \$1,500,000 in cash towards exploration on the Palisades Project. During the second Farm-In period (ended March 31, 2017), JOGMEC contributed \$1,500,000 towards exploration on the Palisades Project. JOGMEC had then earned an unencumbered right, title and benefit to thirty-one point eight seven five percent (31.875%) of the Property. During the third Farm-In Period (extended to March 31, 2019) JOGMEC shall contribute \$1,800,000 towards exploration on the Palisades Project. JOGMEC has committed to fund the entire \$1,800,000 in accordance with its Third Farm-In obligation. It is expected that the funds will be fully expended by March 31, 2019. At July 31, 2018, a total of \$297,333 was receivable from JOGMEC for expenditures they have agreed to fund (2017 - \$536,462).

Currently, JOGMEC has met the requirements of the second Farm-In Period resulting in the respective actual or deemed equitable interests in the Palisades Project of: Altitude 68.125% JOGMEC 31.875%. Provided that JOGMEC has contributed a total amount of CAN\$4,800,000 by the end of third Farm-In Period, the respective actual or deemed equitable interests in the Palisades Project will be: Altitude 49%, JOGMEC 51%.

As a result of the Company's plans with Vibe Bioscience Corporation (Note 15), the Company is divesting of its mining assets. The Company has fully written-off the Palisades property in previous periods.

On August 8, 2013 the Company entered into an Exploration and Option Agreement with Elan Coal Ltd (“Elan”), a company with a related director who is a private non-arm’s length party. Under the terms of the agreement the Company would acquire an option to earn up to 51% interest in Elan’s coal properties upon making an initial cash payment of \$200,000 to Elan to fund field work and completing a financing of a minimum of \$2,000,000. Due to poor financial market conditions the Company was not able to raise the minimum \$2,000,000. Aggregate cumulative net advances made by the Company to Elan through July 31, 2017 totaled \$234,620 which were written down to nil at July 31, 2017.

During the year ended July 31, 2018, the Company converted its cumulative \$234,620 in net advances to Elan (which were previously written down to nil) into a 15% equity interest in Elan. On March 28, 2018 Elan was sold to Atrum Coal Ltd. in a transaction that valued the Company’s 15% equity interest in Elan at \$815,920 – payable in cash of \$465,000 and shares of Atrum Coal Ltd. valued at \$350,920. The gain on the sale of Elan shares over the previous \$234,620 net cumulative advances made by the Company totaled \$581,300 and was recorded as other income with the reversal of the previous write-down of the Elan exploration and evaluation assets recorded as an offset to expenses. The shares, which are traded on the Australian Securities Exchange, are held in escrow for a one-year period (until March 28, 2019).

Vibe Bioscience Ltd.
(Formerly Altitude Resources Inc.)
Notes to the Condensed Interim Consolidated Financial Statements
(Expressed in Canadian Dollars)
For the three and six months ended January 31, 2019
(unaudited)

6. INVESTMENTS

During the year ended July 31, 2018, the Company acquired 2,953,574 common shares of Atrum Coal Limited ("Atrum"), a public company whose shares trade on the Australian Securities Exchange, as partial consideration for the sale of Elan (Note 5). As at July 31, 2018, the Atrum common shares were valued at \$227,425 based on a market price of \$0.08. An unrealized loss on the revaluation of investments of \$123,494 was recorded in the statement of comprehensive income for the change in the fair value of the investment.

During the quarter ended January 31, 2019, the valuation of the investments had increased to approximately \$0.14 based on the market price of Atrum Coal Limited at that date. An unrealized gain on the revaluation of the investments was therefore recorded in the statement of comprehensive income for the change in the fair value of the investment during the three-month period ended January 31, 2019.

7. DUE TO AND FROM RELATED PARTIES

All amounts due from/to related parties are to various shareholders and are non-interest bearing, unsecured and repayable on demand.

8. DUE ON DEMAND LOAN

The due on demand loan is payable in the amount of \$30,000 to a company with a former related director. The principal was due December 15, 2014, bears an annual interest rate of 8% accrued monthly and added to the principal. The loan was convertible into the next financing at the option of the holder. Interest of \$605 is accrued in respect of the three-month period ended January 31, 2019 (\$605 – 2018).

9. SHARE CAPITAL

Authorized, unlimited Class "A" Voting Common Shares.

There have been no changes to share capital for the three and six month period ended January 31, 2019.

10. STOCK OPTIONS AND WARRANTS

(a) Stock options

The Company has a stock option plan to provide officers, directors, employees and consultants of the Company with options to acquire up to 10% of the issued and outstanding common shares of the Company. Under the plan, the minimum exercise price of the options is the market price of the Company's stock on the date of grant. The maximum term of the options is five years and the options generally vest over a three year period, or as determined by the Company's board of directors.

No stock options were issued during the three and six month period ended January 31, 2019.

(b) Warrants

The Company issued 77,779 warrants in the year ended July 31, 2015 which subsequently expired unexercised. As at January 31, 2019, no warrants are outstanding.

Vibe Bioscience Ltd.
(Formerly Altitude Resources Inc.)
Notes to the Condensed Interim Consolidated Financial Statements
(Expressed in Canadian Dollars)
For the three and six months ended January 31, 2019
(unaudited)

11. RELATED PARTY TRANSACTIONS

During the period ended January 31, 2019, \$48,000 (2018 - \$48,000) was paid or accrued to the Chief Executive Officer and Chief Financial Officer as compensation. As at January 31, 2019, \$301,743 (2018 - \$517,943) is payable to the Chief Executive Officer and Chief Financial Officer and is included in accounts payable and accrued liabilities.

12. COMMITMENTS AND CONTINGENCIES

Exploration and evaluation assets

The Company's activities are subject to environmental regulation (including regular environmental impact assessments and permitting) in each of the jurisdictions in which its mineral properties are located. Such regulations cover a wide variety of matters including, without limitation, prevention of waste, pollution and protection of the environment, labour relations and worker safety. The Company may also be subject under such regulations to clean-up costs and liability for toxic or hazardous substances which may exist on or under any of its properties or which may be produced as a result of its operations. It is likely that environmental legislation and permitting will evolve in a manner which will require stricter standards and enforcement. This may include increased fines and penalties for non-compliance, more stringent environmental assessments of proposed projects and a higher degree of responsibility for companies, their directors and employees.

The Company has not determined and is not aware that any provision for such costs is required and is unable to determine the impact on its financial position, if any, of environmental laws and regulations that may be enacted in the future due to the uncertainty surrounding the form that these laws and regulations may take.

13. CAPITAL RISK MANAGEMENT

The Company considers its capital structure to consist of share capital and deficit.

The Company's objective when managing capital is to maintain adequate levels of funding to support its exploration activities and to maintain corporate and administrative functions necessary to support operational activities.

The Company manages its capital structure in a manner that provides sufficient funding for operational activities. Funds are primarily secured through equity capital raised by way of private placements. There can be no assurances that the Company will be able to continue raising equity capital in this manner.

The Company invests all capital that is surplus to its immediate operational needs in short-term, liquid and highly-rated financial instruments, such as cash and other short-term guaranteed deposits, and all are held in a major Canadian financial Institution.

There has been no change in management's capital policy during the period.

The Company is not subject to any externally imposed capital requirements.

Vibe Bioscience Ltd.
(Formerly Altitude Resources Inc.)
Notes to the Condensed Interim Consolidated Financial Statements
(Expressed in Canadian Dollars)
For the three and six months ended January 31, 2019
(unaudited)

14. FINANCIAL INSTRUMENTS AND RISK FACTORS

The Company is exposed to credit risk, market risk (consisting of interest rate risk, and other price risk), and liquidity risk.

(a) Credit Risk

The financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and cash equivalents. The Company mitigates its exposure to credit loss by placing its cash with major financial institutions.

(b) Liquidity Risk

As at January 31, 2019, the Company had accounts payable and accrued liabilities of \$655,122 (July 31, 2018 - \$1,250,574) and cash and cash equivalents of \$6,012 (July 31, 2018 - \$187,431) to meet its current obligations.

(c) Fair Value

Fair value estimates are made at a specific point in time, based on relevant market information and information about the financial instrument. These estimates are subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. Changes in assumptions could significantly affect estimates.

The carrying values of cash and cash equivalents, accounts payable and accrued liabilities, and due from related parties approximate fair values due to the relatively short term maturities of these instruments.

(d) Commodity Price Risk

The ability of the Company to develop its mineral properties and the future profitability of the Company is directly related to the market price of coal and base metals.

Vibe Bioscience Ltd.
(Formerly Altitude Resources Inc.)
Notes to the Condensed Interim Consolidated Financial Statements
(Expressed in Canadian Dollars)
For the three and six months ended January 31, 2019
(unaudited)

15. SUBSEQUENT EVENT

Completion of Amalgamation and Reverse Takeover and disposition of Altitude Resources Ltd. (a previously wholly-owned subsidiary of Altitude Resources Inc.)

On March 25, 2019, subsequent to the period end, the Company completed the Transaction. Pursuant to the Transaction, the Company acquired all of the issued and outstanding shares of Vibe Bioscience Corporation, in exchange for shares in the Company. Vibe Bioscience Corporation was subsequently amalgamated with 2657152 Ontario Inc. Following completion of the Transaction, Altitude Resources Inc. changed its name to Vibe Bioscience Ltd. Under the terms of the amalgamation agreement, former Altitude shareholders own approximately 3% of the Company.

The completion of the Transaction was subject to the satisfaction of various conditions, including but not limited to: (i) the approval of the delisting of the Altitude Shares from the TSX Venture Exchange; (ii) the approval of the listing of the Altitude Shares on the Canadian Securities Exchange (the "CSE") ; (iii) the completion of the Altitude Dispositions; (iv) the approval of the Transaction by the shareholders of Vibe Bioscience Corporation; (v) the approval of various matters related to the Transaction by the shareholders of Altitude; (vi) the completion of satisfactory due diligence by each of the parties; and (vii) other conditions customary for a transaction of this nature. The various approvals of the shareholders was voted on by shareholders of Altitude at a meeting to be held on January 24, 2019. All matters were approved by a super majority of the shareholders of Altitude.

Completion of the Transaction was also conditional on the completion of the Altitude Dispositions. The Altitude Dispositions constituted the sale of all, or substantially all, of the assets of the Company and required shareholder approval in accordance with the provisions of the *Business Corporations Act* (Ontario). The approval of the shareholders of Altitude was received through a vote at the meeting on January 24, 2019.

It is expected that the Common Shares of Vibe will be listed on the CSE, subject to the satisfaction of certain conditions of listing. The Common Shares are expected to trade on the CSE under the symbol "VIBE".

Additional details can be found in the Company's press release dated March 26, 2019 and posted on SEDAR.